Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy: the Phase II/III RAMIRIS Study (AIO-STO-0415)
BMC Cancer（2023）
Key words
Metastatic esophagogastric adenocarcinoma,Ramucirumab,Second line treatment,Paclitaxel,FOLFIRI
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined